Campbell & CO Investment Adviser LLC Acquires Shares of 83,245 Zevra Therapeutics, Inc. $ZVRA

Campbell & CO Investment Adviser LLC bought a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 2nd quarter, Holdings Channel.com reports. The fund bought 83,245 shares of the company’s stock, valued at approximately $733,000.

Other large investors have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in Zevra Therapeutics in the second quarter valued at about $99,000. Strs Ohio acquired a new position in shares of Zevra Therapeutics in the 1st quarter worth approximately $125,000. Corton Capital Inc. bought a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at approximately $156,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its stake in Zevra Therapeutics by 53.8% during the first quarter. EntryPoint Capital LLC now owns 40,675 shares of the company’s stock worth $305,000 after purchasing an additional 14,225 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 19,500 shares of the firm’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the transaction, the chief executive officer owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. This trade represents a 8.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John B. Bode purchased 5,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at $412,200. This represents a 12.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $8.88 on Friday. The company has a 50-day moving average price of $9.58 and a two-hundred day moving average price of $9.62. Zevra Therapeutics, Inc. has a 52 week low of $6.19 and a 52 week high of $13.16. The stock has a market cap of $499.93 million, a price-to-earnings ratio of -42.29 and a beta of 1.52. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.The business had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. Analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZVRA shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Cantor Fitzgerald lowered their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. JMP Securities cut their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Zacks Research lowered Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.